Together with teams at Uppsala University, Antaros presented a poster with the title “Registration based automated lesion detection and therapy evaluation of tumors in whole body PET MR images” today at ESMO 2017 in Madrid (link to abstract). The proposed method, Imiomics, is promising as a quantitative objective measure of total tumour burden to follow therapy effect in clinical studies.

Two of the founders of Antaros Medical, Associate Professor Joel Kullberg and Professor Håkan Ahlström have, together with an Uppsala university colleague, Associate Professor Robin Strand developed the Imiomics tool to fully utilise the huge data set generated by integrated magnetic resonance imaging (MRI) and positron emission tomography (PET) for increased disease understanding, improved diagnoses, and better characterization of therapy effect for individual patients. Continued validation for additional applications is ongoing. Imiomics is expected to be especially useful in diseases where tissues in the whole body can be affected such as metastatic cancer and diabetes.

The ESMO 2017 Congress – Integrating science into oncology for a better patient outcome, in partnership with the European Association for Cancer Research (EACR), brings cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back.